{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:23:52Z","timestamp":1782483832675,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gannex"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40268-023-00444-4","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T18:01:44Z","timestamp":1698948104000},"page":"453-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct04679129","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Handan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzi J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"444_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/164_2019_232","volume":"256","author":"C Gege","year":"2019","unstructured":"Gege C, Hambruch E, Hambruch N, Kinzel O, Kremoser C. Nonsteroidal FXR ligands: current status and clinical applications. Handb Exp Pharmacol. 2019;256:167\u2013205.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"444_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep4.1479","volume":"4","author":"G Parthasarathy","year":"2020","unstructured":"Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun. 2020;4(4):478\u201392.","journal-title":"Hepatol Commun"},{"issue":"2","key":"444_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol hepatol. 2020;17(2):93\u2013110.","journal-title":"Nat Rev Gastroenterol hepatol"},{"issue":"7","key":"444_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterol. 2020;158(7):1851\u201364.","journal-title":"Gastroenterol"},{"key":"444_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","volume":"330","author":"RE Poupon","year":"1994","unstructured":"Poupon RE, Poupon R, Balkau B. UDCA-PBC Study Group Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994;330:1342\u20137.","journal-title":"N Engl J Med"},{"key":"444_CR6","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"RE Poupon","year":"1991","unstructured":"Poupon RE, Balkau B, Eschw\u00e8ge E, Poupon R. UDCA-PBC Study Group A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548\u201354.","journal-title":"N Engl J Med"},{"key":"444_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71:357\u201365.","journal-title":"J Hepatol"},{"issue":"3","key":"444_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000371670","volume":"33","author":"SA Kliewer","year":"2015","unstructured":"Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15\/19 pathway. Dig Dis (Basel, Switzerland). 2015;33(3):327\u201331.","journal-title":"Dig Dis (Basel, Switzerland)"},{"issue":"11","key":"444_CR9","first-page":"654","volume":"14","author":"RS Brown Jr","year":"2018","unstructured":"Brown Jr RS. Use of obeticholic acid in patients with primary biliary cholangitis. Gastroenterol Hepatol. 2018;14(11):654\u20137.","journal-title":"Gastroenterol Hepatol"},{"key":"444_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/a-1877-9656","volume":"42","author":"NW Chew","year":"2022","unstructured":"Chew NW, Ng CH, Truong E, Noureddin M, Kowdley KV. Nonalcoholic steatohepatitis drug development pipeline: an update. Semin Liver Dis. 2022;42:379\u2013400.","journal-title":"Semin Liver Dis"},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u201365.","journal-title":"Lancet"},{"key":"444_CR12","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184\u201396.","journal-title":"Lancet"},{"issue":"9","key":"444_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1139\/apnm-2016-0689","volume":"42","author":"E Z\u00f6hrer","year":"2017","unstructured":"Z\u00f6hrer E, Alisi A, Jahnel J, et al. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab. 2017;42(9):948\u201354.","journal-title":"Appl Physiol Nutr Metab"},{"issue":"6","key":"444_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178580","volume":"12","author":"Z Li","year":"2017","unstructured":"Li Z, Lin B, Lin G, et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS\u00a0One. 2017;12(6): e0178580.","journal-title":"PLoS\u00a0One"},{"key":"444_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111678","volume":"552","author":"K Panzitt","year":"2022","unstructured":"Panzitt K, Zollner G, Marschall HU, Wagner M. Recent advances on FXR-targeting therapeutics. Mol Cell Endocrinol. 2022;552: 111678.","journal-title":"Mol Cell Endocrinol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00444-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00444-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00444-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:15:20Z","timestamp":1700903720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00444-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00444-4","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"19 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Gannex Pharma Co., Ltd. Gannex Pharma was involved with the study design, statistical analysis, interpretation of data, decision to publish, and preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H.H. and J.J.W. are employees and stock\/shareholders of Gannex Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in conformance with good clinical practice (GCP) standards and applicable country and\/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each subject at the screening visit prior to the initiation of any study-related procedures. The investigator or designee explained the study procedures, risks, and potential benefits if any. Subjects reviewed the study instructions and informed consent form (ICF), and were given the time and opportunity to have any questions concerning the conduct of the study, with all answered to their satisfaction.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Any additional information required to reanalyze the data reported in this paper is available from the corresponding author upon request from the publication of the paper. Requests for data sharing will be responded to within 2\u20133 weeks.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Jinzi J. Wu: design and conduct of the study including safety surveillance; interpretation of results; critical review and revision of the manuscript; and approval of the final manuscript for submission. Handan He: PK, PD, and biomarker statistical analyses; interpretation of results; and critical review and revision of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}